Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Coherus Bio (NQ: CHRS ) 1.880 -0.030 (-1.57%) Streaming Delayed Price Updated: 4:00 PM EDT, May 28, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Coherus Bio < Previous 1 2 3 4 5 6 7 8 9 Next > Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting May 23, 2024 From Coherus BioSciences, Inc. Via GlobeNewswire Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA May 23, 2024 From Coherus BioSciences, Inc. Via GlobeNewswire CHRS Stock Earnings: Coherus BioSciences Misses EPS, Misses Revenue for Q1 2024 May 09, 2024 CHRS stock results show that Coherus BioSciences missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. Via InvestorPlace Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update May 09, 2024 From Coherus BioSciences, Inc. Via GlobeNewswire Recap: Coherus BioSciences Q4 Earnings March 13, 2024 Via Benzinga Earnings Preview For Coherus BioSciences March 12, 2024 Via Benzinga Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan May 09, 2024 From Coherus BioSciences, Inc. Via GlobeNewswire Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer May 08, 2024 From Coherus BioSciences, Inc. Via GlobeNewswire Coherus to Report First Quarter 2024 Financial Results on May 9, 2024 May 01, 2024 From Coherus BioSciences, Inc. Via GlobeNewswire Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting April 24, 2024 From Coherus BioSciences, Inc. Via GlobeNewswire Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting April 08, 2024 From Coherus BioSciences, Inc. Via GlobeNewswire Why Coherus Biosciences Stock Tumbled on Thursday March 14, 2024 The company fell well short of expectations for its fourth quarter. Via The Motley Fool Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update March 13, 2024 From Coherus BioSciences, Inc. Via GlobeNewswire Earnings Scheduled For March 13, 2024 March 13, 2024 Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million. Via Benzinga Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024 March 05, 2024 From Coherus BioSciences, Inc. Via GlobeNewswire Coherus Completes Divestiture of Ophthalmology Franchise March 04, 2024 From Coherus BioSciences, Inc. Via GlobeNewswire Coherus BioSciences Announces New Employment Inducement Grants February 23, 2024 From Coherus BioSciences, Inc. Via GlobeNewswire Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv February 21, 2024 From Coherus BioSciences, Inc. Via GlobeNewswire Why Coherus BioSciences Stock Jumped Today February 06, 2024 As promised, Coherus is using the proceeds of a recent divestiture to pay down debt and reduce interest expenses. Via The Motley Fool Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP February 05, 2024 From Coherus BioSciences, Inc. Via GlobeNewswire Why Coherus BioSciences Stock Is Sinking Today January 23, 2024 The positive reaction to Coherus' sale of its ophthalmology franchise to Sandoz didn't last long. Via The Motley Fool Why Coherus Biosciences Popped Today January 22, 2024 Coherus is divesting its non-core ophthalmology franchise. Via The Motley Fool Why CommScope Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Monday's Mid-Day Session January 22, 2024 Shares of CommScope Holding Company, Inc. (NASDAQ: COMM) fell sharply during Monday’s session. B of A Securities analyst Tal Liani downgraded CommScope from Neutral to Underperform and lowered the... Via Benzinga Why Is Cancer Immunotherapy Focused-Coherus BioSciences Stock Trading Higher Today? January 22, 2024 Coherus BioSciences agreed to sell its ophthalmology franchise for $170M to Sandoz. This aligns with CHRS' focus on oncology and will help reduce debt and overhead costs. Via Benzinga Why Is Cartesian Therapeutics (RNAC) Stock Down 5% Today? January 22, 2024 Cartesian Therapeutics stock is falling on Monday as investors react to a delisting notice for RNAC shares due to its low trading price. Via InvestorPlace Why Is B. Riley Financial (RILY) Stock Down 11% Today? January 22, 2024 B. Riley Financial stock is falling on Monday as RILY investors react to reports of an SEC probe and the company's stance on the news. Via InvestorPlace Topics Regulatory Compliance Exposures Legal Regulatory Why Is Coherus BioSciences (CHRS) Stock Up 17% Today? January 22, 2024 Coherus BioSciences stock is rising on Monday as CHRS investors react to a $170 million divestment of its CIMERLI ophthalmology franchise. Via InvestorPlace Why Coherus BioSciences Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket January 22, 2024 Shares of Coherus BioSciences, Inc. (NASDAQ: CHRS) shares rose sharply in today’s pre-market trading after the company announced an agreement to divest ophthalmology franchise to Sandoz in $170 million... Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday January 22, 2024 We're starting the trading week with a breakdown of the biggest pre-market stock movers worth knowing about on Monday! Via InvestorPlace Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal January 22, 2024 From Coherus BioSciences, Inc. Via GlobeNewswire < Previous 1 2 3 4 5 6 7 8 9 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.